RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced it will be presenting at the SNN Network Virtual Conference on Monday, August 3rd at 2:30 PM EDT. Dr. Heman Chao, Helix’s Chief Executive Officer will be hosting the presentation and answering questions from attendees.
- 0 Comments
- FY2020